{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:29Z","timestamp":1761518849972},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4570,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1093\/annonc\/mdm076","type":"journal-article","created":{"date-parts":[[2007,3,18]],"date-time":"2007-03-18T00:00:36Z","timestamp":1174176036000},"page":"1015-1020","source":"Crossref","is-referenced-by-count":12,"title":["A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"C.","family":"Natoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cianchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Grassadonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ricevuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.I.","family":"Rispoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm076_bb0010","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/1097-0142(19900915)66:14+<1387::AID-CNCR2820661414>3.0.CO;2-I","article-title":"Comprehensive management of locally advanced breast cancer","volume":"66","author":"Hortobagyi","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm076_bb0015","first-page":"3","article-title":"Indications for neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Bear","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0020","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0025","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.2000.18.7.1558","article-title":"Primary systemic therapy in operable breast cancer","volume":"18","author":"Wolff","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm076_bb0040","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph nodes response to doxorubicin-based chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0045","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1008337009350","article-title":"Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm. A unicentre randomised trial with a 124-month median follow-up. Institut Bergoni Bordeaux Groupe Sein (IBBGS)","volume":"10","author":"Mauriac","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0055","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2001.19.15.3506","article-title":"Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimilating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study","volume":"19","author":"Von Minckwitz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0060","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.3816\/CBC.2002.s.015","article-title":"Aberdeen Breast Group: neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial","volume":"2","author":"Heys","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdm076_bb0065","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0070","first-page":"17","article-title":"Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial","volume":"16","author":"O'Shaughnessy","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.1093\/annonc\/mdm076_bb0075","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm076_bb0080","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm076_bb0085","first-page":"945","article-title":"Enhancement of immunohistochemical reactivity for thymidine phosphorilase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients","volume":"7","author":"Kurosumi","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdm076_bb0090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0006-2952(99)00099-4","article-title":"Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells","volume":"58","author":"Grem","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1093\/annonc\/mdm076_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.11-90001-20","article-title":"Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer","volume":"11","author":"Wardley","year":"2006","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm076_bb0100","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 10","key":"10.1093\/annonc\/mdm076_bb0105","first-page":"S3","article-title":"Evolving concepts in the systemic drug therapy of breast cancer","volume":"24","author":"Norton","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0110","first-page":"7067","article-title":"A gompertzian model of human breast cancer growth","volume":"48","author":"Norton","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm076_bb0115","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0959-8049(99)00258-0","article-title":"Optimizing chemotherapy dose density and dose intensity: new strategies to improve outcomes in adjuvant therapy for breast cancer","volume":"36","author":"Gianni","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm076_bb0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdm076_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm076_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdm076_bb0135","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polichemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Early Breast Cancer Trialist's Collaborative Group.","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm076_bb0140","first-page":"39a","article-title":"Predictive factors for a complete pathologic response (pCR) in primary breast cancer treated neoadjuvantly with a epirubicin\/taxane + G-CSF regimen","volume":"20","author":"Steger","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0145","first-page":"34a","article-title":"First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST)on local-regional disease","volume":"21","author":"Gianni","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0150","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1200\/JCO.1999.17.9.2649","article-title":"Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and loco-regional treatment","volume":"17","author":"Thames","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdm076_bb0155","first-page":"464","article-title":"Primary chemotherapy in operable breast cancer","volume":"23","author":"Bonadonna","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0160","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease women with operable breast cancer: finding from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0165","first-page":"133a","article-title":"Neoadjuvant (high-dose doxorubicin) plus adjuvant CMF chemotherapy for stages II e IIIA breast cancer: a phase II study","volume":"19","author":"Delgado","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0170","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","article-title":"Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel","volume":"17","author":"von Minckwitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0175","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomised pilot trial of the Hoosier Oncology Group","volume":"17","author":"Miller","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0180","first-page":"69","article-title":"Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +\/- tamoxifen in locally advanced breast cancer","volume":"64","author":"Valero","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm076_bb0185","first-page":"69","article-title":"Phase II combining docetaxel and doxorubicin in the neoadjuvant setting in patients with operable breast carcinoma: final results","volume":"64","author":"Tubiana-Hulin","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm076_bb0190","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2001.19.15.3506","article-title":"Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomised, controlled open phase IIb study","volume":"19","author":"von Minckwitz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0195","first-page":"133a","article-title":"Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study","volume":"21","author":"Untch","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0200","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0205","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","article-title":"Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate","volume":"16","author":"Chevallier","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdm076_bb0215","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome","volume":"180","author":"Sataloff","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1093\/annonc\/mdm076_bb0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1998.99","article-title":"Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer","volume":"77","author":"Honkoop","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm076_bb0225","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomised trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/6\/1015\/665837\/mdm076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:21:51Z","timestamp":1582197711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0923753419379098"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm076","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}